Cargando…
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
BACKGROUND: Skin manifestations of Tuberous Sclerosis Complex (TSC) cause significant morbidity. The molecular mechanism underlying TSC is understood and there is evidence that systemic treatment with rapamycin or other mTOR inhibitors may be a useful approach to targeted therapy for the kidney and...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266897/ https://www.ncbi.nlm.nih.gov/pubmed/18226258 http://dx.doi.org/10.1186/1471-5945-8-1 |